NCT04393805.

Study name	Heparins for thromboprophylaxis in COVID‐19 patients: HETHICO study in Veneto
Starting date	1 June 2020
Contact information	Paolo Simioni Department of Medicine, University of Padua, Italy +39 0498212667 | paolo.simioni@unipd.it
Methods	Multicentre, retrospective cohort, open label, investigator‐sponsored, two hospitalised population arms (ICU and wards). A comparison of anticoagulant types and doses is foreseen as secondary analysis.
Participants	877 participants, ≥ 18 years, female and male Inclusion criteria proved SARS‐COVID‐2 infection Exclusion criteria none
Interventions	ICU group: thromboprophylaxis with LMWH, mostly enoxaparin Ward group: thromboprophylaxis with LMWH, mostly enoxaparin
Outcomes	Primary Bleeding (time frame: 28 days). Collect and evaluate in real‐life the safety data of the anticoagulant treatments used by estimating the incidence of bleeding complications during hospitalisation. Thrombosis (time frame: 28 days). Collect and evaluate in real‐life the efficacy data of the anti‐coagulant treatments used by estimating the incidence of DVT and/or PE during hospitalisation. Mortality (time frame: 28 days). Collect and evaluate in real‐life the data by estimating incidence of intra‐hospital death. Secondary Worsening (time frame: 28 days). Clinical worsening with transfer to the intensive/sub‐intensive clinical care unit Length of stay (time frame: 60 days)
Notes	NCT04393805 | No data provided